US 10,639,325 B2 · Polysaccharide-polyamine copolymer and use thereof in reducing uric acid concentration in plasma

Abstract

Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients. The polysaccharide-polyamine copolymer is formed by copolymerization of the following two parts: a selectively oxidized polysaccharide with 2,3-dialdehydo, and a polyamine with an amino functional group; the polyamine with an amino functional group and the selectively oxidized polysaccharide with 2,3-dialdehydo can form a net structure by means of covalent crosslinking, resulting in a hydrogel with an amino functional group or a granular polysaccharide-polyamine copolymer, wherein the amino functional group in the hydrogel with an amino functional group or the granular polysaccharide-polyamine copolymer can be protonated so as to form a cationic copolymer of a three-dimensional network structure having a protonated site, and the nitrogen content of the cationic copolymer and the nitrogen content of the polysaccharide-polyamine copolymer are above 12.3 wt %, and both the cationic copolymer and the polysaccharide-polyamine copolymer are water-insoluble.

Claims20

Dependent claims

A pharmaceutical composition for treatments of hyperuricemia, the pharmaceutical composition comprises an amino-polysaccharide copolymer and a pharmaceutically acceptable salt thereof as an active ingredient, the amino-polysaccharide copolymer is a copolymerization product of the following two parts:

a selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, and an amino polymer which provides an amino functionality;
the amino polymer cross linking the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety to form a net-like structure and finally to provide a hydrogel having an amino functionality or a particulate amino-polysaccharide copolymer, amino functionalities of the hydrogel having an amino functionality or the particulate amino-polysaccharide copolymer can be protonated to form a cationic copolymer having three dimensional network structure and protonation sites, a nitrogen content of the cationic copolymer or the amino-polysaccharide copolymer is at least 12.3% weight percent, or at least 15% weight percent, or at least 22% weight percent, or at least 40% weight percent, the cationic copolymer and the amino-polysaccharide copolymer are both insoluble in water,
wherein in the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, a ratio of an amount of oxidized glucose units to the total amount of glucose units is at least 50%, at least 70%, or at least 80%.

A method for reducing serum uric acid comprising administering a pharmaceutical composition comprising an amino-polysaccharide copolymer and a pharmaceutically acceptable salt thereof as an active ingredient, wherein, the amino-polysaccharide copolymer is a copolymerization product of the following two parts:

a selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, and an amino polymer which provides an amino functionality;
the amino polymer cross linking the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety to form a net-like structure and finally to provide a hydrogel having an amino functionality or a particulate amino-polysaccharide copolymer, amino functionalities of the hydrogel having an amino functionality or the particulate amino-polysaccharide copolymer can be protonated to form a cationic copolymer having three dimensional network structure and protonation sites, a nitrogen content of the cationic copolymer or the amino-polysaccharide copolymer is at least 12.3% weight percent, or at least 15% weight percent, or at least 22% weight percent, or at least 40% weight percent, the cationic copolymer and the amino-polysaccharide copolymer are both insoluble in water;
wherein in the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, a ratio of an amount of oxidized glucose units to the total amount of glucose units is at least 50%, at least 70%, or at least 80%.

Dependencies are inferred from the claim text.

Polysaccharide-polyamine copolymer and use thereof in reducing uric acid concentration in plasma

Life of this patent

Polysaccharide-polyamine copolymer and use thereof in reducing uric acid concentration in plasma

Life of this patent

Abstract

Claims20